Prominent publications by Jorge Sérgio Reis‐Filho

KOL Index score: 18193

IntroductionDespite strong evidence regarding the role of CCND1 amplification and protein overexpression in breast carcinoma, the associations between CCND1 amplification/cyclin D1 overexpression and clinicopathological variables and clinical outcome remain controversial.Aims of the study(1) to correlate cyclin D1 expression with gene amplification; (2) to analyse the correlations between CCND1 amplification and overexpression with clinicopathological features and patients’ outcome in ...

Also Ranks for: Ccnd1 Amplification |  d1 expression |  breast cancer |  patient outcome |  situ hybridisation
KOL Index score: 17406

Amplification of fibroblast growth factor receptor 1 (FGFR1) occurs in approximately 10% of breast cancers and is associated with poor prognosis. However, it is uncertain whether overexpression of FGFR1 is causally linked to the poor prognosis of amplified cancers. Here, we show that FGFR1 overexpression is robustly associated with FGFR1 amplification in two independent series of breast cancers. Breast cancer cell lines with FGFR1 overexpression and amplification show enhanced ...

Also Ranks for: Fgfr1 Amplification |  therapy resistance |  breast cancers |  type 1 receptors |  cell growth
KOL Index score: 17352

Conflicting results on the prevalence of cyclin D1 ovexpression and its correlation with CCND1 amplification and outcome of breast cancer patients have been reported. Owing to limited sensitivity and specificity of most antibodies against cyclin D1, evaluation of cyclin D1 immunoexpression is reported to be problematic. The aims of this study were to assess the prevalence of cyclin D1 expression in breast carcinomas using the SP4 rabbit monoclonal antibody; to correlate cyclin D1 ...

Also Ranks for: Ccnd1 Amplification |  cyclin d1 |  breast carcinomas |  situ hybridisation |  estrogen receptors
KOL Index score: 16665

Phyllodes tumours (PTs) are breast fibroepithelial lesions that are graded based on histological criteria as benign, borderline or malignant. PTs may recur locally. Borderline PTs and malignant PTs may metastasize to distant sites. Breast fibroepithelial lesions, including PTs and fibroadenomas, are characterized by recurrent MED12 exon 2 somatic mutations. We sought to define the repertoire of somatic genetic alterations in PTs and whether these may assist in the differential diagnosis ...

Also Ranks for: Tert Promoter |  phyllodes tumours |  malignant pts |  actionable mutations |  massively parallel sequencing
KOL Index score: 16510

This study was undertaken to determine the morphologic features and frequency of putative precursor lesions involved in the development of some pure forms of special types and low grade breast carcinoma. We reviewed 147 successive tumor cases, comprising tubular carcinoma (TC); pure type (n=56) and mixed type (n=20), invasive lobular carcinoma (ILC); classic type (n=57), and tubulolobular carcinoma (TLC; n=14). The presence of preinvasive lesions including columnar cell lesions (CCLs), ...

Also Ranks for: Lobular Neoplasia |  tubular carcinoma |  columnar cell lesions |  low grade |  adh dcis
KOL Index score: 16494

INTRODUCTION: Metaplastic breast carcinomas constitute a heterogeneous group of neoplasms, accounting for less than 1% of all invasive mammary carcinomas. Approximately 70-80% of metaplastic breast carcinomas overexpress the epidermal growth factor receptor (EGFR). Human epidermal growth factor receptor (HER)2 and EGFR have attracted much attention in the medical literature over the past few years owing to the fact that humanized monoclonal antibodies against HER2 and therapies directed ...

Also Ranks for: Gene Amplification |  metaplastic breast |  situ hybridization |  egfr her2 |  monoclonal antibody
KOL Index score: 15992

BACKGROUND: The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are associated with breast cancer risk as high as those associated with rare BRCA2 mutations. We aimed to estimate the relative risks associated with specific rare variants in PALB2, CHEK2 and ATM via a multicentre case-control study.

METHODS: We genotyped 10 rare mutations ...

Also Ranks for: Cancer Risk |  chek2 atm |  evidence association |  mutations palb2 |  checkpoint kinase
KOL Index score: 15174

PURPOSE: The oncogenic drivers of triple-negative (TN) and basal-like breast cancers are largely unknown. Substantial evidence now links aberrant signaling by the fibroblast growth factor receptors (FGFR) to the development of multiple cancer types. Here, we examined the role of FGFR signaling in TN breast cancer.

EXPERIMENTAL DESIGN: We examined the sensitivity of a panel of 31 breast cancer cell lines to the selective FGFR inhibitor PD173074 and investigated the potential mechanisms ...

Also Ranks for: Cell Lines |  fgfr signaling |  erbb2 receptors |  oncogene proteins |  breast neoplasms
KOL Index score: 15101

PurposeAberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in breast cancers from patients treated with neoadjuvant anti-HER2-targeted therapy without chemotherapy.Patients and methodsBaseline tumor samples from patients with HER2-positive breast cancer enrolled in TBCRC006 (NCT00548184), a ...

Also Ranks for: Pik3ca Mutation |  chemotherapy patients |  lapatinib trastuzumab |  pten status |  breast cancers
KOL Index score: 15096

BACKGROUND: We aimed to assess the clinical validity of circulating tumour cell (CTC) quantification for prognostication of patients with metastatic breast cancer by undertaking a pooled analysis of individual patient data.

METHODS: We contacted 51 European centres and asked them to provide reported and unreported anonymised data for individual patients with metastatic breast cancer who participated in studies between January, 2003, and July, 2012. Eligible studies had participants ...

Also Ranks for: Clinical Validity |  ctc count |  pooled analysis |  tumour cell |  individual patient data
KOL Index score: 14908

Approximately 8% of breast cancers show increased copy numbers of chromosome 17 centromere (CEP17) by fluorescence in situ hybridization (FISH) (ie average CEP17 >3.0 per nucleus). Currently, this pattern is believed to represent polysomy of chromosome 17. HER2-amplified cancers have been shown to harbour complex patterns of genetic aberrations of chromosome 17, in particular involving its long arm. We hypothesized that aberrant copy numbers of CEP17 in FISH assays may not necessarily ...

Also Ranks for: Situ Hybridization |  chromosome 17 |  breast cancer |  centromeric region |  centromere copy
KOL Index score: 14876

BACKGROUND: p63 is a p53 homologue that is mapped to chromosome 3q27. This gene encodes six different isoforms, which have either transactivating or dominant negative effects on p53-reporter genes. It has been described that in contrast to p53, p63 seems not to be associated with tumor predisposition, as neither p63 knockout mouse models nor germline p63 mutations are related to an increased risk of tumorigenesis. It has been demonstrated that p63 is a reliable keratinocyte stem cell ...

Also Ranks for: P63 Expression |  normal skin |  tumor carcinoma |  basal cells |  sweat glands
KOL Index score: 14841

The mechanisms underlying the progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) of the breast are yet to be fully elucidated. Several hypotheses have been put forward to explain the progression from DCIS to IDC, including the selection of a subpopulation of cancer cells with specific genetic aberrations, and the acquisition of new genetic aberrations or non-genetic mechanisms mediated by the tumour microenvironment. To determine whether synchronously ...

Also Ranks for: Ductal Carcinoma |  genetic heterogeneity |  dcis idc |  clonal selection |  situ hybridization
KOL Index score: 14580

We have previously provided evidence showing an association between some precursor lesions with low nuclear grade breast carcinomas (LNGBCs). In this study, further immunophenotypic support to our proposed route of pathogenesis of LNGBC and their precursor lesions was provided. Precursor lesions including columnar cell lesions, atypical ductal hyperplasia, ductal carcinoma in situ, usual epithelial hyperplasia, and lobular neoplasia were compared with matching "morphologically normal" ...

Also Ranks for: Precursor Lesions |  grade breast |  lobular neoplasia |  ataxia telangiectasia |  cyclin d1
KOL Index score: 14561

HER2 and TOP2A are targets for the therapeutic agents trastuzumab and anthracyclines and are frequently amplified in breast cancers. The aims of this study were to provide a detailed molecular genetic analysis of the 17q12–q21 amplicon in breast cancers harbouring HER2/TOP2A co-amplification and to investigate additional recurrent co-amplifications in HER2/TOP2A-co-amplified cancers. In total, 15 breast cancers with HER2 amplification, 10 of which also harboured TOP2A amplification, as ...

Also Ranks for: Cell Lines |  her2 top2a |  genomic analysis |  breast cancer |  human pair

Key People For Breast Cancer

Top KOLs in the world
Ahmedin * *****
united states breast cancer addis ababa
Gabriel * **********
breast cancer neoadjuvant chemotherapy estrogen receptors
Rebecca * ******
united states colorectal cancer incidence rates
Charles * *****
breast cancer gene expression intrinsic subtypes
Freddie *** ****
cancer incidence nordic countries mortality rates
Jacques ******
cancer incidence global burden latin america

Jorge Sérgio Reis‐Filho:Expert Impact

Concepts for whichJorge Sérgio Reis‐Filhohas direct influence:Breast cancer,  Breast cancers,  Situ hybridization,  Gene expression,  Breast carcinoma,  Breast neoplasms,  Estrogen receptors,  Gene amplification.

Jorge Sérgio Reis‐Filho:KOL impact

Concepts related to the work of other authors for whichfor which Jorge Sérgio Reis‐Filho has influence:Breast cancer,  Gene expression,  Tumor cells,  Triple negative,  Estrogen receptor,  Situ hybridization,  Liquid biopsy.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA; email: | Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA | Memorial Sloan Kettering Cancer Center, New York,